These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 9334588)

  • 1. Urinary interleukin-8/creatinine level as a predictor of response to intravesical bacillus Calmette-Guerin therapy in bladder tumor patients.
    Rabinowitz R; Smith DS; Tiemann DD; Hudson MA
    J Urol; 1997 Nov; 158(5):1728-31; discussion 1731-2. PubMed ID: 9334588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
    de Reijke TM; de Boer EC; Kurth KH; Schamhart DH
    J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
    Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
    J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary interleukin-2 monitoring during prolonged bacillus Calmette-Guerin treatment: can it predict the optimal number of instillations?
    de Reijke TM; De Boer EC; Kurth KH; Schamhart DH
    J Urol; 1999 Jan; 161(1):67-71. PubMed ID: 10037371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of urinary interleukin-8 cutoff point for recurrences after transurethral resection plus induction bacillus Calmette-Guérin treatment in non-muscle-invasive bladder tumors.
    Sagnak L; Ersoy H; Ozok U; Senturk B; Ercil H; Bahar G; Ozturk E
    Clin Genitourin Cancer; 2009 Aug; 7(2):E16-23. PubMed ID: 19692317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-8 expression in the urine after bacillus Calmette-Guerin therapy: a potential prognostic factor of tumor recurrence and progression.
    Thalmann GN; Dewald B; Baggiolini M; Studer UE
    J Urol; 1997 Oct; 158(4):1340-4. PubMed ID: 9302115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
    Shintani Y; Sawada Y; Inagaki T; Kohjimoto Y; Uekado Y; Shinka T
    Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary fibronectin levels in patients treated with intravesical bacillus Calmette-Guérin for superficial bladder cancer.
    Danişman A; Bulut K; Kukul E; Ozen I; Sevük M
    Urol Int; 2000; 64(4):198-201. PubMed ID: 10895085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer.
    de Boer EC; Somogyi L; de Ruiter GJ; de Reijke TM; Kurth KH; Schamhart DH
    Urol Res; 1997; 25(1):31-4. PubMed ID: 9079743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary interleukin-8 predicts the response of standard and low dose intravesical bacillus Calmette-Guerin (modified Danish 1331 strain) for superficial bladder cancer.
    Kumar A; Dubey D; Bansal P; Mandhani A; Naik S
    J Urol; 2002 Nov; 168(5):2232-5. PubMed ID: 12394765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Assessment of 8-hydroxy-2'-deoxyguanosine concentrations in bladder cancer patients treated with intravesical BCG instillation].
    Kaczmarek P; Błaszczyk J; Fijałkowski P; Sierakowska-Fijałek A; Niemirowicz J; Kasprzak A; Baj Z
    Pol Merkur Lekarski; 2005 Oct; 19(112):526-8. PubMed ID: 16379317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravesical combined chemoimmunotherapy with epirubicin and bacillus Calmette-Guérin is not indicated for superficial bladder cancer.
    Tozawa K; Okamura T; Sasaki S; Kawai N; Ito Y; Hayashi Y; Kohri K
    Urol Int; 2001; 67(4):289-92. PubMed ID: 11741130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin.
    Kamat AM; Briggman J; Urbauer DL; Svatek R; Nogueras González GM; Anderson R; Grossman HB; Prat F; Dinney CP
    Eur Urol; 2016 Feb; 69(2):197-200. PubMed ID: 26119560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra.
    Taylor JH; Davis J; Schellhammer P
    Clin Genitourin Cancer; 2007 Sep; 5(6):386-9. PubMed ID: 17956711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary interleukins in patients receiving intravesical Bacillus Calmette-Guerin therapy for superficial bladder cancer.
    Fleischmann JD; Toossi Z; Ellner JJ; Wentworth DB; Ratliff TL; Imbembo AL
    Cancer; 1989 Oct; 64(7):1447-54. PubMed ID: 2789094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of urinary interleukin-2, interleukin-2 receptor, and tumor necrosis factor levels in patients with superficial bladder tumors after intravesical BCG immunotherapy.
    Balbay D; Ozen H; Ozkardes H; Barut A; Bakkaloglu M; Tasar C; Remzi D
    Urology; 1994 Feb; 43(2):187-90. PubMed ID: 8116114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor.
    Coplen DE; Marcus MD; Myers JA; Ratliff TL; Catalona WJ
    J Urol; 1990 Sep; 144(3):652-7. PubMed ID: 2388321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG.
    Haaff EO; Catalona WJ; Ratliff TL
    J Urol; 1986 Oct; 136(4):970-4. PubMed ID: 3489840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serial urinary IL-2, IL-6, IL-8, TNFalpha, UBC, CYFRA 21-1 and NMP22 during follow-up of patients with bladder cancer receiving intravesical BCG.
    Sanchez-Carbayo M; Urrutia M; Romani R; Herrero M; Gonzalez de Buitrago JM; Navajo JA
    Anticancer Res; 2001; 21(4B):3041-7. PubMed ID: 11712808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors.
    Eto M; Koga H; Noma H; Yamaguchi A; Yoshikai Y; Naito S
    Urol Int; 2005; 75(2):114-8. PubMed ID: 16123563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.